DERM Company Profile and Key Details

DERM has shown sold momentum, gaining 12.79% over the past week and 21.25% over the past quarter, though year-to-date performance is up 13.23%. Short-term trend indicators are bearishly aligned (SMA20 4.43%, SMA50 7.28%, SMA200 14.83%). The stock’s 14-day RSI is 59.62 (neutral), while the ATR of 0.47 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -8.84% below its high and over 75.25% above its low. Average 10-day trading volume of 133.18 thousand shares is below the 3-month average of 241.12 thousand, indicating normal recent market interest.

The latest quarter delivered EPS of -$0.01. The next quarter is forecast at -$0.05. Next year's EPS is expected at -$122.58. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $13.00 to $13.00. The high target offers 79.81% upside. The low target suggests 79.81% downside. The mean target is $13.00. This offers 79.81% upside. Journey Medical Corporation earnings surprise history is a mixed track record. The quarter that ended August 12, 2026, missed forecasts by -55.56%. The prior quarter beat by 14.29%. Over the last six quarters, Apple has recorded several small beats. These include -25.0% in May 14, 2025.

Journey Medical Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$7.73. This means the shares are trading below this model’s fair value.

Journey Medical Corporation has 22.22 million shares outstanding. The public float is 15.59 million shares, elevated short interest at 18.97% of float. This equals 2.87 million shares. The short ratio is 17.88 days. Institutional investors hold 87.96% of the float. Insiders own 32.77%. KOLLURI KRISHNA KITTU holds 3.50 million shares, KERINS PATRICK J has 3.50 million shares and DRANT RYAN D has 3.50 million shares.

Journey Medical Corporation (NASDAQ:DERM) closed at $7.23 USD, gaining $0.14 (1.97%) from the previous close of $7.09. The stock is currently mid-range between its 52-week high and low $4.31 and $9.55. With a market capitalization of about $198.98 million, Journey Medical Corporation is classified as a micro-cap and shows market-like volatility (beta ~1.10). Key stats such as the average daily volume over the past year has been around 243.68 thousand shares, volume is running light vs its 52-week average. Headquartered in Scottsdale, AZ, Journey Medical Corporation operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Claude Maraoui, the company employs approximately 58 people and listed since November 12, 2021. Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States.

Journey Medical Corporation (NASDAQ:DERM) shares are up 13.23% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Journey Medical Corporation trading at a premium to the broader market with a P/E of -32.18. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.64, suggesting 33.33% upside. Our AI forecast model points to short-term strength (8.16% over two weeks), a medium-term rise (27.66% over three months), and a longer-term gain (266.67% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Journey Medical Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.16%, with price expected at $7.82 by September 25, 2026, within a range of $7.53 to $8.13 3-Month Outlook: Projected rise of 27.66%, reaching $9.23 by December 10, 2026, with a range of $8.72 to $9.68. 1-Year Outlook: Projected gain of 266.67%, with price at $26.51 by September 10, 2027, within a range of $17.51 to $37.94.

Journey Medical Corporation trades at a P/E ratio of -32.18, slightly below the S&P 500 average, with a price-to-sales ratio of 2.93 and a price-to-book ratio of 6.22 trading at moderately above to book value. The P/FCF stands at -26.71, also below market averages.